Interview: MerLion builds on its strengths as it looks to new areas
This article was originally published in Scrip
Executive Summary
With several products moving towards mid-stage clinical development, ongoing discussions with potential licensing partners, a revised business structure and a new round of financing, there is plenty to keep Dr Tony Buss busy.